But when it finally came, the company was ready with two major drugs, Skyreezy and Renvoke. It worked. This week, Avy reported earnings that beat analyst estimates and raised its 2026 outlook. Even if you aren't familiar with the name Abby, you've probably seen some of their commercials. >> There's nothing like clearer skin and better movement. >> This week, the company delivered a solid earnings beat driven by its immunology portfolio of drugs that sent the stock up, recovering from recent losses. Yet, inv ...

AbbVie Inc. (NYSE:ABBV) is one of the best drug stocks to buy according to analysts. AbbVie Inc. (NYSE:ABBV) announced on April 27 the submission of an application to the U.S. Food and Drug Administration (FDA) seeking approval for SKYRIZI® for subcutaneous induction for the treatment of adult patients with moderately to severely active Crohn’s disease. Management stated that the application is supported by the recently shared positive data from the Phase 3 AFFIRM study evaluating the efficacy and safety o ...

AbbVie Inc. (NYSE:ABBV) is included among the 10 Best Large Cap Dividend Growth Stocks to Invest in. On April 30, Bank of America analyst Tim Anderson upgraded AbbVie Inc. (NYSE:ABBV) to Buy from Neutral. It also lifted the price target on the stock to $234 from $226. The firm believes concerns around competitive erosion in the key immunology segment are "overdone." It points to strong forward indicators for Skyrizi and says new competitors appear to be "category expanding." With durable growth expected int ...

When I last checked on pharmaceutical stock AbbVie ( ABBV ) in January, a price correction was on the cards, as the company was due to sign the MFN agreement and its market multiples were elevated too. This has played out, with over a Manika is a macroeconomist with over 20 years of experience in industries including investment management, stock broking, investment banking. She also runs the profile Long Term Tips [LTT], which focuses on the generational opportunity in the green economy. Her investing group ...

华尔街机构评级变动汇总 主要看涨升级 - 德意志银行将SiteOne Landscape评级从持有上调至买入 目标价维持在160美元 认为其一季报公布后股价下跌反应过度 [2] - 雷蒙德詹姆斯将Equinix评级从大市表现大幅上调至强力买入 目标价1250美元 认为公司在去年调整后已重回主导地位 并正受益于人工智能相关需求 [2] - 美国银行将艾伯维评级从中性上调至买入 目标价从226美元上调至234美元 认为市场对关键免疫学领域竞争侵蚀的担忧过度 Skyrizi的前瞻性指标依然强劲 新竞争者似乎是在扩大市场类别 [3] - 摩根大通将泰瑞达评级从中性上调至超配 目标价维持在400美元 此次评级上调主要基于估值考量 因其在财报公布后股价已下跌20% [3] - Summit Insights将高通评级从持有上调至买入 认为随着公司向人工智能领域转型 负面因素已反映在股价中 [4] 主要看跌降级 - 摩根大通将Meta Platforms评级从超配下调至中性 目标价从825美元下调至725美元 尽管其一季度营收同比增长33%令人鼓舞 但公司增加的基础设施支出以及人工智能产品管线能见度不足是下调评级的原因 [5] - B. Riley将Etsy评级从买入下调至中性 目标价从70美元上调至75美元 认为财报公布后的上涨使风险与回报趋于平衡 [5] - 高盛将Wingstop评级从买入下调至中性 目标价从290美元大幅下调至190美元 认为该品牌面临比预期更严峻的宏观经济和竞争阻力 [5] - 高盛将GE HealthCare评级从买入下调至中性 目标价从81美元下调至65美元 认为其面临的宏观环境压力将掩盖其业务改善的部分 如管线开发和新产品发布执行 [5] - 美国银行将Reliance评级从中性下调至弱于大盘 目标价从355美元上调至365美元 尽管短期基本面仍有支撑 但股价上行空间现在更多地受到估值制约 [5]

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month Accessibility Statement Skip Navigation Through its loyalty rewards program All, Allergan Aesthetics will donate to The Skin Cancer Foundation $10 for every new member who joins from a referral in May, up to $100,000. IRVINE, Calif., April 30, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, today announced a charitable initiative in recognition of Skin Cancer Awareness Month. Throughout ...

To ensure this doesn't happen in the future, please enable Javascript and cookies in your browser. If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

AbbVie Inc. (NYSE:ABBV) is a leading global biopharmaceutical company dedicated to the discovery, development, and sale of innovative pharmaceutical drugs. The company strategically focuses on creating advanced treatments for complex and serious diseases. Its core therapeutic areas, including immunology, oncology, and neuroscience, position it as a key player in the competitive pharmaceutical industry. Other key investment metrics provide a broader perspective on AbbVie's overall financial position. AbbVie' ...

AbbVie Q1 Revenue Beats Driven By Immunology Growth Sales increased 12.4% on a reported basis or 10.3% on an operational basis. The company reported adjusted earnings of $2.65 per share, up 7.7%, beating the consensus of $2.59. Global net revenues from the immunology portfolio were $7.29 billion, up 16.4% (+14.3% on an operational basis), including Skyrizi sales, which increased 30.9% to $4.48 billion; Rinvoq sales reached $2.12 billion, an increase of 23.3%; and Humira sales fell 38.6% to $688 million. Neu ...

Performance beat was driven by robust market share gains in immunology and neuroscience, which management describes as the company's primary growth engines. Skyrizi's outperformance is attributed to its best-in-class profile and leadership in psoriatic disease, where it maintains a share lead of over 4x versus the nearest competitor. The neuroscience portfolio is achieving industry leadership status, with migraine and psychiatry franchises delivering double-digit growth and share gains. Management is utiliz ...